Diet & Nutrition News and Research

Latest Diet & Nutrition News and Research

Masimo granted FDA clearance for Pronto-7 noninvasive hemoglobin spot-check testing device

Masimo, the inventor of Masimo Rainbow Pulse CO-Oximetry™, Masimo Rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, today announced FDA 510(k) clearance for the Pronto-7™—a new handheld device designed for quick and easy noninvasive hemoglobin (SpHb®) spot-check testing, along with SpO2, pulse rate, and perfusion index, in virtually any environment.

28 Jun 2010

Clinical study results show no increased risk of CV events associated with SYMLIN injection

Amylin Pharmaceuticals, Inc. today announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular events associated with SYMLIN (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA (exenatide) injection added to Lantus (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association (ADA), showing that this investigational compound, a dipeptidyl peptidase (DPP)-4 inhibitor, achieved significant, sustained and clinically meaningful reductions in blood glucose as measured by haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) concentrations.(1-6) Linagliptin is being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes.

28 Jun 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.

28 Jun 2010

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

Healthier cafeteria choices, longer and more intense periods of physical activity and robust in-school education programs can lower rates of obesity and other risk factors for type 2 diabetes, according to a national study called HEALTHY.

28 Jun 2010

International child health experts to converge for Excellence in Paediatrics

International child health experts to converge on London for Excellence in Paediatrics. Experts from all over the world will be converging on the Park Plaza Hotel in Westminster, London, from 2 - 4 December 2010 for Excellence in Paediatrics, which promises cutting edge topics by outstanding speakers.

28 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.

28 Jun 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor, for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models.

28 Jun 2010

Researchers discover genetic links to kidney failure, diabetic kidney disease

Researchers at the Translational Genomics Research Institute will make two presentations at this week's 70th Scientific Sessions of the American Diabetes Association, June 25-29, in Orlando, Florida.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than Januvia plus metformin at 52 weeks.

28 Jun 2010

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

The cause of diabetes during pregnancy is directly controlled by serotonin, a chemical produced by the body and normally known as a neurotransmitter, and is influenced by the amount of protein in the mother's diet early in pregnancy, according to new findings of an international team led by researchers at UCSF.

28 Jun 2010

ARS study finds link between vitamin D and cognitive function

At a time when consumer interest in health-enhancing foods is high, Agricultural Research Service (ARS)-funded scientists have contributed to a limited but growing body of evidence of a link between vitamin D and cognitive function.

25 Jun 2010

Research findings suggest possible diagnostic test for ALS

A team led by a Los Angeles Biomedical Research Institute researcher developed a novel approach to efficiently identify disease relevant genes in human complex neurological disorders and demonstrated the effectiveness of this method by applying it to Amyotrophic Lateral Sclerosis, or Lou Gehrig's Disease, according to a new study reported online in the journal, Human Molecular Genetics.

25 Jun 2010

Scientists report first preliminary description of bed bug's sialome

With bed bugs reemerging as a nuisance in some parts of the country, scientists are reporting the first preliminary description of the bug's sialome - the saliva proteins that are the secret to Cimex lectularius' ability to suck blood from its human victims and escape to bite again with risking a lethal slap. The findings, which could have medical applications in diagnosing bed bug bites and preventing the itch, appear in ACS' monthly Journal of Proteome Research.

25 Jun 2010

Study on effects of resveratrol on metabolism of microcebus murinus

Resveratrol is a natural substance that is widely studied, for its anti-ageing properties among other things. For the first time, work by a team in the "Mécanismes adaptatifs : des organismes aux communautés" Laboratory (CNRS/Muséum National d'Histoire Naturelle) has revealed that this compound reduces weight gain in lemurs. Such findings provide new information regarding the effects of resveratrol on energy metabolism and the control of body mass in primates. They may give a clearer understanding of the factors that govern obesity in humans. This study is published on 22 June 2010 in /BMC Physiology/.

25 Jun 2010

Digoxin drug may increase risk of premature death in patients with kidney disease

For patients with kidney disease on dialysis, the widely used heart medication digoxin may lead to an increased risk of premature death, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

25 Jun 2010

Diet & Nutrition News and Research

Latest Diet & Nutrition News and Research

Masimo granted FDA clearance for Pronto-7 noninvasive hemoglobin spot-check testing device

Clinical study results show no increased risk of CV events associated with SYMLIN injection

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Linagliptin mono- and combination therapy improves blood glucose control

Merck challenges New York jury decision in federal FOSAMAX retrial

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

International child health experts to converge for Excellence in Paediatrics

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Researchers discover genetic links to kidney failure, diabetic kidney disease

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

New findings could lead to simple dietary solutions, possible therapeutics for gestational diabetes

ARS study finds link between vitamin D and cognitive function

Research findings suggest possible diagnostic test for ALS

Scientists report first preliminary description of bed bug's sialome

Study on effects of resveratrol on metabolism of microcebus murinus

Digoxin drug may increase risk of premature death in patients with kidney disease

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diet & Nutrition News and Research

Latest Diet & Nutrition News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in